This marks MC-Rx’s second acceptance at the prestigious event. 

The abstract will be showcased and deliberated among attendees nationwide, with publication in the JMCP Abstract supplement. The intervention aims to disseminate current HIV PREP guidelines to physicians and pharmacists, while identifying and addressing barriers to compliance. Presentations are scheduled for Wednesday, April 17, from 11:30 am to 2:30 pm, at the Ernest N. Morial Convention Center in New Orleans, LA, during the AMCP 2024 Conference, April 15-18.

Marileny Lugo, President of MC-Rx, expressed gratitude, stating, "We are honored to present our research at AMCP, another significant milestone for our organization. In alignment with our commitment to patient health and safety, our project underscores the strategic role PBMs play in promoting educational efforts and fostering medication adherence strategies to achieve optimal HIV PREP efficacy while ensuring significant cost avoidance. Being selected for presentation is an opportunity to advance patient safety and health."

About MC-Rx:

MC-Rx is a leading direct-source pharmacy benefit management solutions provider dedicated to enhancing cost containment, clinical optimization, and member satisfaction. Focusing on innovative PBM strategies, MC-Rx delivers customized programs supported by clinical expertise, analytics, operations, and compliance, ultimately improving patient health outcomes while reducing costs.